Skip to main content
TipRanks
Go Ultimate75% OFF

ImmuPharma (25I) AI Stock Analysis

0 Followers
DE:25I

ImmuPharma

(Frankfurt:25I)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Low leverageDebt at or near zero in most periods lowers default and refinancing pressure, preserving flexibility for a development-stage company. This gives ImmuPharma more room to direct scarce capital toward clinical programmes and partnerships, although it does not offset operating losses.
Negative Factors
Minimal revenue baseRevenue is effectively zero in recent annual periods and TTM, leaving no established operating revenue base to fund research. Until a candidate is partnered on meaningful terms or commercialized, progress depends heavily on external financing and successful clinical development.

ImmuPharma (25I) vs. iShares MSCI Germany ETF (EWG)

-100%-80%-60%-40%-20%0%20%DE:25I-82.14%EWG+10.70%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 17.59M
Dividend Yield
―
Average Volume (3M)
16.25K
Price to Earnings (P/E)
-2.3
Beta (1Y)
6.21
Revenue Growth
―
EPS Growth
8.57%
Country
Germany
Employees
7
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

ImmuPharma Business Overview & Revenue Model

Company Description

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company’s lead p...

ImmuPharma Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:25I against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:SBTXGB:SBTX59NeutralGBP 12.31M-26.39-5.25%―95.16%85.60%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:SCLPGB:SCLP49NeutralGBP 98.19M-4.63128.87%―-100.00%-30.39%
GB:SARGB:SAR47NeutralGBP 23.75M-6.04-188.01%――28.78%
GB:HEMOGB:HEMO46NeutralGBP 46.90M-3.76-409.57%――18.57%
GB:POLBGB:POLB42NeutralGBP 44.66M-7.50-71.28%――31.58%

* Healthcare Sector Average

Performance Comparison

0%100%DE:25IGB:SARGB:SCLPGB:HEMOGB:SBTXGB:POLBDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:25I and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:25IImmuPharma plc0.01-0.08-83.87%
GB:SARSareum Holdings14.500.755.45%
GB:SCLPScancell Holdings81.00-17.00-17.35%
GB:HEMOHemogenyx Pharmaceuticals Plc680.00-220.00-24.44%
GB:SBTXSkinBioTherapeutics plc4.75-11.00-69.84%
GB:POLBPoolbeg Pharma Ltd.5.851.8044.44%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.